We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




3D Mammography System Gains Approval in US

By HospiMedica International staff writers
Posted on 28 Feb 2011
The first X-ray mammography device that provides three-dimensional (3D) images of the breast for breast cancer screening and diagnosis has been approved for use in the United States. More...


Given the limitations of conventional 2D imaging, about 10% of women undergo additional testing after the initial screening exam for abnormalities that are later determined to be noncancerous.

The US Food and Drug Administration (FDA; Silver Spring, MD, USA) approved the Selenia Dimensions system, an upgrade to Hologic's existing FDA-approved 2D system, which can provide 2D and 3D X-ray images of the breasts. The 3D images may help physicians effectively detect and diagnose breast cancer. "Physicians can now access this unique and innovative 3D technology that could significantly enhance existing diagnosis and treatment approaches,” said Jeffrey Shuren, MD, JD, director of the FDA's Center for Devices and Radiological Health (Silver Spring, MD, USA).

The US National Cancer Institute (Bethesda, MD, USA) recommends women ages 40 and older have a mammogram every one to two years. Nearly 40 million mammograms are performed each year in the United States. As part of the approval process, the FDA reviewed results from two studies where board-certified radiologists were asked to review 2D and 3D images from more than 300 mammography exams. In both studies, radiologists viewing both the 2D and 3D images obtained a 7% improvement in their ability to differentiate between cancerous and noncancerous cases compared to viewing 2D images alone.

While the combination of the Selenia's 2D and 3D images approximately doubled the radiation dose the patient received, it improved the accuracy with which radiologists detected cancers, decreasing the number of women recalled for a diagnostic workup. There is uncertainty for radiation risk estimates; however, the increase in cancer risk from having both a 2D and 3D scan is expected to be less than 1.5% compared to the natural cancer incidence, and less than 1% compared to the risk from traditional 2D mammography.
The Mammography Quality Standards Act requires that all healthcare professionals obtain eight hours of training prior to using new mammography technology on patients. The FDA also requires that the manufacturer provide each facility with a manual clearly defining the tests required for initial, periodic, and yearly quality control measures.

The Selenia Dimensions system is marketed by Hologic, Inc. (Bedford, MA, USA).

Related Links:
Hologic



Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Electrode Solution and Skin Prep
Signaspray
Medical Monitor
VITALMAX 4100SL
Silver Member
ECG Management System
NEMS Web
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.